[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Ozer N, Deveci OS, Kaya EB, Demircin M: Mediastinal lymphoma causing extrinsic pulmonary stenosis. Turk Kardiyol Dern Ars; 2009 Sep;37(6):421-4
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal lymphoma causing extrinsic pulmonary stenosis.
  • A 20-year-old female was referred to our center with a cystic mass detected by transthoracic echocardiography and thoracic computed tomography, in the superoanterior mediastinum, 5.5 x 5.5 x 7 cm in size, causing main pulmonary trunk compression.
  • The pathological diagnosis of the mass was stage IIa nodular sclerosing Hodgkin's lymphoma.
  • The patient received postoperative chemotherapy and thoracal radiotherapy.
  • [MeSH-major] Lymphoma / complications. Mediastinal Neoplasms / complications. Pulmonary Valve Stenosis / etiology
  • [MeSH-minor] Echocardiography, Transesophageal. Female. Humans. Pulmonary Artery / surgery. Pulmonary Artery / ultrasonography. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20019459.001).
  • [ISSN] 1016-5169
  • [Journal-full-title] Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
  • [ISO-abbreviation] Turk Kardiyol Dern Ars
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


2. Hervás Benito I, Vera Espallardo F, Saura Quiles A, González Cabezas P, Bello Arques P, Rivas Sánchez A, Alonso Monfort J, Pérez Velasco R, Mateo Navarro A: [Thyroid scintigraphy and body scanning with 67 Ga in a case of primary thyroid lymphoma]. Rev Esp Med Nucl; 2001 Oct;20(6):462-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thyroid scintigraphy and body scanning with 67 Ga in a case of primary thyroid lymphoma].
  • The fine needle aspiration-puncture (FNAP) lead to a diagnosis of thyroiditis.
  • The pathological diagnosis was diffuse large cell primary thyroid lymphoma (PTL).
  • The PTL is a rare entity that accounts for less than 1% of all the Non-Hodgkin's lymphomas.
  • The thyroid scintigraphy showed the existence of a cold nodule in the left thyroid lobule and the 67Ga scan revealed a large abnormal lesion in the mediastinum that extended to the right latero-cervical region.
  • After two chemotherapy courses, the 67Ga scan was normal.
  • [MeSH-major] Gallium Radioisotopes. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Radiopharmaceuticals. Thyroid Gland / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Diagnostic Errors. Doxorubicin / administration & dosage. Humans. Mediastinal Neoplasms / radionuclide imaging. Mediastinal Neoplasms / therapy. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Radiotherapy, Adjuvant. Remission Induction. Thyroidectomy. Thyroiditis / diagnosis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11578581.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 10
  •  go-up   go-down


3. Ruiz-Hernández G, Scaglione C, Delgado-Bolton RC, Gutiérrez-García A, Madero L, Jiménez-Vicioso A, Carreras-Delgado JL: [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF]. Rev Esp Med Nucl; 2004 Mar-Apr;23(2):124-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF].
  • The thoracic CT showed a bulky mediastinal mass that occupied the pretracheal, paratracheal and right prevascular regions.
  • Biopsy of the mediastinal mass revealed the presence of diffuse large B-cell non-Hodgkin's lymphoma.
  • Treatment included 4 cycles of chemotherapy followed by 7 days of subcutaneous granulocyte colony-stimulating factor (G-CSF, Lenogastrim) at a dose of 5 mg/Kg/day.
  • Following treatment, a CT scan was performed to evaluate response, finding a calcification of the mass without significant reduction of the overall size.
  • Because CT was inconclusive in the assessment of response to therapy, a 18F-FDG PET scan was performed.
  • The 18F-FDG PET scan did not show any pathological uptake in the mediastinum but revealed a splenic and bone marrow diffusely increased 18F-FDG uptake.
  • The differential diagnosis included a secondary effect induced by G-CSF therapy as one of the main possibilities, but other possibilities such as a malignant infiltration by lymphoma could not be discarded.
  • We consider that the stimulating effect that G-CSF therapy has on the spleen and bone marrow must be taken into account when performing a 18F-FDG PET scan, as it can be an important source of false-positive results.
  • [MeSH-major] Bone Marrow / metabolism. Bone Marrow / radionuclide imaging. Fluorodeoxyglucose F18 / metabolism. Granulocyte Colony-Stimulating Factor / adverse effects. Radiopharmaceuticals / metabolism. Spleen / metabolism. Spleen / radionuclide imaging. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15000944.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


Advertisement
4. Shimizu J, Ishida Y, Takehara A, Kinoshita T, Tatsuzawa Y, Kawaura Y, Matsumoto I, Imai M: Salvage surgery for primary non-Hodgkin's lymphoma of the thyroid gland with histopathological complete response to radio-chemotherapy: report of a case. Surg Today; 2003;33(1):45-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery for primary non-Hodgkin's lymphoma of the thyroid gland with histopathological complete response to radio-chemotherapy: report of a case.
  • An open biopsy confirmed a diagnosis of non-Hodgkin's lymphoma of the thyroid (NHLT), of a diffuse large cell type.
  • The patient was referred to our department for radio-chemotherapy for stage I E NHLT.
  • She was given radiotherapy in the form of 40 Gy radiation directed at her neck and superior mediastinum, with one course of chemotherapy using cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP).
  • After radio-chemotherapy, the tumor was obviously smaller.
  • Because the patient refused further chemotherapy, she underwent salvage surgery, after being sufficiently advised, and with her informed consent.
  • Histological examination of the removed thyroid tissue showed that the radio-chemotherapy had produced a complete response.
  • Thus, we believe that an open biopsy should be performed early to confirm the diagnosis of lymphoma histologically and to determine the degree of malignancy.
  • We also stress the fact that NHLT is presently most effectively treated by radiotherapy combined with several courses of CHOP chemotherapy.
  • The role of surgery in the treatment of NHLT is diminishing.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / surgery. Thyroid Neoplasms / surgery
  • [MeSH-minor] Aged. Biopsy. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Humans. Prednisolone / administration & dosage. Salvage Therapy. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12560906.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


5. Van Den Berg H, Verhulst L, Behrendt H, Staalman CR: Persistent mediastinal mass is not indicative of recurrence after chemotherapy only in paediatric Hodgkin's disease. Br J Haematol; 2000 Apr;109(1):104-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent mediastinal mass is not indicative of recurrence after chemotherapy only in paediatric Hodgkin's disease.
  • Most patients with Hodgkin's disease are treated with chemotherapy in conjunction with radiotherapy, but at the end of treatment a residual mass is often present.
  • After combined therapy, it has been assumed that no additional treatment is needed.
  • However, for children treated without radiotherapy, no data exist on the relevance of a residual mediastinal mass to risk of relapse.
  • We report on the findings of follow-up thorax radiographs of a group of 27 children with initial mediastinal involvement, who were treated with chemotherapy only.
  • We conclude that the regression rate of the mediastinal mass was not related to a later recurrence.
  • Regression after chemotherapy without radiotherapy is probably slower than after combined therapy.
  • When the data were compared with a group of children with Hodgkin's disease without mediastinal involvement, we found that survival was not related to initial mediastinal involvement.
  • [MeSH-major] Hodgkin Disease / radiography. Mediastinal Neoplasms / radiography. Neoplasm Recurrence, Local / radiography. Neoplasm, Residual / radiography
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10848788.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


6. Akhtar S, Abdelsalam M, El Weshi A, Al Husseini H, Janabi I, Rahal M, Maghfoor I: High-dose chemotherapy and autologous stem cell transplantation for Hodgkin's lymphoma in the kingdom of Saudi Arabia: King Faisal specialist hospital and research center experience. Bone Marrow Transplant; 2008 Aug;42 Suppl 1:S37-S40
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous stem cell transplantation for Hodgkin's lymphoma in the kingdom of Saudi Arabia: King Faisal specialist hospital and research center experience.
  • We report our experience with high-dose chemotherapy (HDC) and autologous SCT (ASCT) in 66 patients out of 113 (113 patients out of 153 had complete analysis) with primary refractory Hodgkin's lymphoma (PR-HL) who received salvage chemotherapy followed by BEAM as HDC.
  • Before salvage chemotherapy, stages I:II:III:IV were 2:21:14:29, bulky disease 27%, involvement of mediastinum 79%, spleen 26% and extranodal site 47%; 92% had ESHAP (etoposide, methylprednisolone, high-dose cytarabine, cisplatin) as salvage.
  • Post-ASCT evaluation showed response in 50 patients (76%), complete response (CR) in 37 (56%), partial response in 14 (21%), no response or stable disease in three (5%) and progressive disease in 10 (15%) patients.
  • From diagnosis and HDC, median follow-up is 38.5 and 22.8 months and median overall survival 78 and 57 months, respectively.
  • Twenty-two (33%) patients died of the disease.
  • Multivariate analysis showed elevated lactic dehydrogenase (LDH) for EFS (P=0.041) and mediastinal involvement for OS (P=0.038) as negative prognostic factors.
  • Elevated LDH and mediastinal involvement are poor prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724297.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Ayadi-Kaddour A, Mlika M, Kilani T, El Mezni F: A primary mediastinal Hodgkin's lymphoma with asymptomatic myasthenia gravis: a rare association. Pathologica; 2008 Jun;100(3):170-2
MedlinePlus Health Information. consumer health - Myasthenia Gravis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A primary mediastinal Hodgkin's lymphoma with asymptomatic myasthenia gravis: a rare association.
  • It has been only rarely reported in association with thymic Hodgkin's lymphoma.
  • Simple chest radiography showed a heterogeneous mediastinal mass.
  • Thoracic computed tomography revealed an antero-superior mediastinal mass measuring 6 cm and invading the upper lobe of the left lung with parenchymal micronodules of the left lung and an involvement of mediastinal nodes.
  • In order to consider a diagnosis of thymoma, electromyography was performed despite the fact that the patient was asymptomatic.
  • After stabilising the MG with symptomatic therapies, surgical intervention was performed.
  • Histological and immunohistochemical findings led to the diagnosis of thymic Hodgkin's lymphoma.
  • The patient is currently receiving complementary chemotherapy.
  • An association between asymptomatic MG and thymic Hodgkin's lymphoma has not been documented in the literature, and the present case appears to be the first reported.
  • The treatment of thymic Hodgkin's lymphoma is based on Cotswold staging system.
  • [MeSH-major] Hodgkin Disease / complications. Mediastinal Neoplasms / complications. Myasthenia Gravis / complications

  • Genetic Alliance. consumer health - Myasthenia gravis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841821.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Zhen ZJ, Sun XF, Xia Y, Wang ZH, Ling JY: [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. Ai Zheng; 2006 Apr;25(4):471-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
  • BACKGROUND & OBJECTIVE: Reactive thymic hyperplasia following chemotherapy for malignant tumors is likely to be misdiagnosed as tumor residue or relapse, therefore, leads to unnecessary treatment.
  • This study was to analyze the clinical features of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma.
  • METHODS: Clinical data of 13 children with reactive thymic hyperplasia following chemotherapy for malignant lymphoma, treated from Mar.
  • Of the 13 cases, 5 were Hodgkin's disease (HD), and 8 were non-Hodgkin's lymphoma (NHL).
  • All patients received computed tomography (CT) to evaluate the therapeutic effect.
  • When a new thymic mass emerged, positive electron tomography/computed tomography (PET/CT) was performed to identify its quality.
  • RESULTS: At diagnosis, 10 patients had mediastinal involvement.
  • Reactive thymic hyperplasia occurred following the completion of chemotherapy in 9 cases, or during the maintenance of chemotherapy in 4 cases.
  • CT showed that the longest diameters of the new mediastinal masses were 2.2-6.0 cm (mean 3.7 cm).
  • The interval from last chemotherapy cycle to the occurrence of thymic hyperplasia was 2-12 months (mean 4 months).
  • PET/CT was performed to 5 cases, and showed no vital tumors in the mediastinum.
  • Three cases were misdiagnosed as tumor residue or relapse, and received second-line therapy.
  • CONCLUSIONS: Reactive thymic hyperplasia may occur following intensive chemotherapy for childhood malignant lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Mediastinal Neoplasms / drug therapy. Thymus Hyperplasia / chemically induced
  • [MeSH-minor] Adolescent. Bleomycin / adverse effects. Bleomycin / therapeutic use. Child. Child, Preschool. Dacarbazine / adverse effects. Dacarbazine / therapeutic use. Disease-Free Survival. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Positron-Emission Tomography. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Tomography, X-Ray Computed. Vinblastine / adverse effects. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Thymic hyperplasia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613683.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; ABVD protocol; IE protocol; MOPP protocol
  •  go-up   go-down


9. Cracco C, Divine M, Maitre B: [Thoracic involvement in Hodgkin's lymphoma]. Rev Mal Respir; 2007 Oct;24(8):999-1012
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thoracic involvement in Hodgkin's lymphoma].
  • [Transliterated title] Atteintes thoraciques au cours des lymphomes hodgkiniens.
  • INTRODUCTION: Hodgkin's lymphoma is defined by a malignant prolifération of Reed-Sternberg or Hodgkin cells that are clonally related B-cell-derived malignant cells.
  • This disease is characterized by a good outcome (cure rate more than 80%).
  • Initial thoracic involvement is usual and the more frequent localization is the mediastinum, following by the lung parenchyma and the pleura.
  • In the last two cases, histological diagnosis is warranted since this involvement modified the staging and the prognosis of the disease.
  • Functional deficiency following mediastinal radiotherapy and chemotherapy (including bleomycin) is often detected, whatever this is associated with symptom or CT scan abnormalities.
  • Granulomatous disease can be associated at any time during the disease and differential diagnosis from relapse is often difficult.
  • PERSPECTIVES AND CONCLUSIONS: Hodgkin lymphoma patients are more likely to die from acute and late treatment-related toxicities and the major task is to reduce treatment associated toxicity while maintaining cure rate.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Thoracic Neoplasms / diagnosis. Thoracic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18033187.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 73
  •  go-up   go-down


10. Akhtar S, El Weshi A, Abdelsalam M, Hussaini H, Janabi I, Rahal M, Maghfoor I: Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Bone Marrow Transplant; 2007 Oct;40(7):651-8
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
  • We report our experience with high-dose chemotherapy (HDC) and autologous SCT (ASCT) in 66 patients with primary refractory Hodgkin's lymphoma (PR-HL) who received salvage chemotherapy followed by BEAM as HDC.
  • Before salvage chemotherapy, stages I:II:III:IV were 2:21:14:29, bulky disease 27%, involvement of mediastinum 79%, spleen 26% and extranodal site 47%, 92% had ESHAP as salvage.
  • Post-ASCT evaluation showed response in 50 patients (76%); complete response (CR) 37 (56%), partial response 14 (21%), no response or stable disease 3 (5%) and progressive disease in 10 (15%).
  • Another five patients achieved CR after radiation therapy and one after surgery, making total CR 43 (65%).
  • From diagnosis and HDC, median follow-up is 38.5 and 22.8 months and median overall survival (OS) 78 and 57 months, respectively.
  • Twenty-two patients (33%) died due to disease.
  • Multivariate analysis showed elevated lactate dehydrogenase (LDH) for EFS (P=0.041) and mediastinal involvement for OS (P=0.038) as negative prognostic factors.
  • Elevated LDH and mediastinal involvement are poor prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Carmustine / administration & dosage. Child. Cohort Studies. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Multivariate Analysis. Neoplasm Staging. Podophyllotoxin / administration & dosage. Prognosis. Retrospective Studies. Salvage Therapy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660837.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM protocol
  •  go-up   go-down


11. Tang YJ, Tang JY, Pan C, Xue HL, Chen J, Shen SH, Dong L, Zhou M, Wang YP, Gu LJ, Jiang H, Ye QD: [Clinical characteristics and treatment outcome of 36 cases with non-Hodgkin's lymphoma arising from mediastinum in children]. Zhonghua Er Ke Za Zhi; 2009 Sep;47(9):687-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and treatment outcome of 36 cases with non-Hodgkin's lymphoma arising from mediastinum in children].
  • OBJECTIVE: Non-Hodgkin's lymphoma (NHL) presenting as mediastinal mass is usually progressive and may cause severe respiratory distress and death.
  • This study aimed to summarize the clinical features and prognosis of NHL arising from mediastinum.
  • METHODS: Totally 36 patients with NHL arising from mediastinum reported herein were diagnosed between 1999 and 2007.
  • Their clinical characteristics, pathologic classification, diagnosis, outcome of different treatment protocol were retrospectively analyzed.
  • Diagnosis was established on pathology that was achieved by mediastinal mass or peripheral lymph nodes biopsy, while some were diagnosed based on bone marrow or pleural effusion cytology study and immunophenotyping.
  • Patients who experienced superior vena cava syndrome (SVCS) and/or superior mediastinum syndrome (SMS) received induction chemotherapy with cyclophosphamide (C), vincristine (O) and prednisone (P) for one week.
  • RESULTS: Twenty-seven cases experienced mediastinal mass or peripheral lympho nodes biopsy and were diagnosed by histopathology and immunohistochemistry.
  • Of them, 24 were lymphoblastic lymphoma and 3 were anaplastic large cell lymphoma.
  • All the 36 cases were T-cell type.
  • Twenty-four patients had urgent situation of SVCS and airway obstruction, 22 patients reached good response after emergency management including COP induction chemotherapy and pleural effusion suction.
  • Twenty-nine cases achieved complete remission (CR) while in 6 patients the disease relapsed.
  • Thirteen patients died from disease progression, relapse or severe infection during chemotherapy.
  • CONCLUSION: Establishment of a diagnosis as soon as possible was important to reduce the mortality and improve long term survival of patients.
  • Induction chemotherapy for emergency situation was efficacious.
  • The regimen of T-NHL-CCCG97, T-NHL-2002, and B-NHL-2001 for NHL arising from mediastinum based on pathological classification is feasible.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Mediastinal Neoplasms
  • [MeSH-minor] Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021793.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


12. Ionescu I, Brice P, Simon D, Guermazi A, Leblanc T, Rousselot P, Gossot D, Meignin V, Gisselbrecht C, Rain JD: Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients. Med Oncol; 2000 May;17(2):127-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients.
  • Following treatment of mediastinal Hodgkin's disease (HD), residual masses are frequent and gallium scanning has proven to be of value in the evaluation of their specificity (fibrosis or active disease).
  • This study assessed, for relapse and survival, the predictive value of restaging gallium scan of patients with a residual mass on computed tomography scan after induction chemotherapy.
  • Between 1/89 and 12/97, in 53 newly diagnosed HD patients with a residual mediastinal mass, a gallium scan was performed after chemotherapy (3 or 4 courses) and always before consolidative radiotherapy.
  • Characteristics at diagnosis were: nodular sclerosis histology, 89%; bulky mediastinal disease, 79%; B-symptoms, 51%.
  • Evaluation with gallium scan after induction chemotherapy identifies chemosensitive patients among those with poor-prognosis mediastinal HD.
  • Although relapse may occur in patients with negative gallium scan, a postive gallium scan is highly predictive of failure and poor outcome, and treatment should thus be modified.
  • [MeSH-major] Gallium Radioisotopes. Hodgkin Disease / diagnostic imaging. Mediastinal Neoplasms / diagnostic imaging

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Eur J Haematol. 1989 Apr;42(4):344-7 [2721659.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:53-6 [9187430.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] J Nucl Med. 1992 Mar;33(3):345-50 [1740700.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):518-27 [9053473.001]
  • [Cites] Nucl Med Commun. 1999 Jan;20(1):13-20 [9949408.001]
  • [Cites] Cancer. 1993 Jul 15;72 (2):577-82 [8319190.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):239-52 [2578012.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):754-9 [9477109.001]
  • [Cites] J Nucl Med. 1993 Aug;34(8):1326-30 [8326393.001]
  • [Cites] Clin Nucl Med. 1995 Apr;20(4):293-8 [7788982.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 2:59-63 [8204521.001]
  • [Cites] Radiology. 1987 Jul;164(1):111-4 [3495815.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1631-7 [9193363.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12 ):1966-70 [2230889.001]
  • [Cites] Cancer. 1988 Jun 15;61(12 ):2439-43 [3365666.001]
  • [Cites] J Nucl Med. 1997 Jun;38(6):990-4 [9189158.001]
  • [Cites] Hematol Cell Ther. 1997 Apr;39(2):59-65 [9168301.001]
  • [Cites] J Clin Oncol. 1994 Feb;12 (2):306-11 [8113837.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Semin Nucl Med. 1995 Jan;25(1):60-71 [7716559.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1173-86 [1694235.001]
  • [Cites] Nouv Rev Fr Hematol. 1993 Aug;35(4):457-61 [8414967.001]
  • [Cites] Nuklearmedizin. 1999;38(1):24-30 [9987778.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1124-33 [9305714.001]
  • (PMID = 10871819.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes
  •  go-up   go-down


13. Karakas Z, Agaoglu L, Taravari B, Saribeyoglu E, Somer A, Guler N, Unuvar A, Anak S, Yalcin I, Devecioglu O: Pulmonary tuberculosis in children with Hodgkin's lymphoma. Hematol J; 2003;4(1):78-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary tuberculosis in children with Hodgkin's lymphoma.
  • The clinical presentation of tuberculosis (TB) and Hodgkin's lymphoma (HL) with pulmonary involvement is similar and raises problems of differential diagnosis.
  • It may also be difficult to distinguish TB from relapsed lymphoma.
  • The purpose of this study was to evaluate the association of HL and pulmonary TB and to discuss differential diagnosis.
  • A total of 27 patients (38%) had mediastinal-pulmonary involvement initially.
  • In all, 14 patients (20%) had pulmonary TB; three of them were diagnosed as having TB before HL, two of them had TB and HL concomittantly at initial diagnosis, seven of them during lymphoma therapy and two of them after the cessation of lymphoma treatment.
  • In all, 11 patients with pulmonary TB had diffuse pulmonary infiltrations and mediastinal enlargement at lung contrast-enhanced computed tomography and X-ray, which was difficult to differentiate from HL.
  • To evaluate mediastinal lymphadenopathies is very crucial and the differential diagnosis is difficult; hence the association between HL and the TB must be considered especially in countries where TB is highly endemic.

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12692526.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antitubercular Agents
  • [Number-of-references] 11
  •  go-up   go-down


14. Hofbauer GF, Boehler A, Speich R, Burg G, Nestle FO: Painless erythema of the hands associated with non-Hodgkin's lymphoma in a lung transplant recipient. J Am Acad Dermatol; 2002 May;46(5 Suppl):S159-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Painless erythema of the hands associated with non-Hodgkin's lymphoma in a lung transplant recipient.
  • Acral erythema limited to the fingers or the hands has been described in systemic disease.
  • Six weeks after transplantation, rapidly growing large-cell immunoblastic non-Hodgkin's lymphoma of the lungs and mediastinum was diagnosed.
  • Therapy was reduction of immunosuppression and 12 cycles of extracorporeal photophoresis.
  • After 4 months, lymphoma was in clinical and radiologic remission.
  • Acral erythema has been reported in association with chemotherapy, collagen vascular disease, infections as with HIV, hepatitis C virus, parvovirus B19, or cytomegalovirus.
  • [MeSH-major] Cystic Fibrosis / surgery. Erythema / immunology. Lung Transplantation / adverse effects. Lymphoma, Non-Hodgkin / etiology. Paraneoplastic Syndromes / diagnosis
  • [MeSH-minor] Adolescent. Female. Follow-Up Studies. Hand Dermatoses / immunology. Hand Dermatoses / therapy. Humans. Immunocompromised Host. Risk Assessment

  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12004301.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Win PK, Popescu I, Nicoloff R: Unusual case presentation of lichen simplex chronicus, Hodgkin's lymphoma, and nonpuerperal hyperprolactinemia-galactorrhea. Endocr Pract; 2001 Sep-Oct;7(5):388-91
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual case presentation of lichen simplex chronicus, Hodgkin's lymphoma, and nonpuerperal hyperprolactinemia-galactorrhea.
  • OBJECTIVE: To report the association of nonpuerperal galactorrhea and severe pruritus with clinical stage IIB Hodgkin's lymphoma.
  • Computed tomography showed multiple enlarged mediastinal lymph nodes, and a left supraclavicular lymph node biopsy revealed the presence of Reed-Sternberg cells and lymphocyte alterations consistent with the diagnosis of Hodgkin's lymphoma.
  • After one cycle of chemotherapy for management of the lymphoma, parallel reductions in serum prolactin concentrations and galactorrhea were noted.
  • CONCLUSION: Possible causes for this syndrome include afferent mammary nerve stimulation resulting from scratching of pruritic skin and cytokine-induced hypersecretion of prolactin attributable to the lymphoma.
  • Although uncommon, this syndrome may serve as an important harbinger of developing Hodgkin's lymphoma, and its disappearance may signify a therapeutic response.
  • [MeSH-major] Galactorrhea / complications. Hodgkin Disease / complications. Hyperprolactinemia / complications. Neurodermatitis / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / radiography. Lymphocytes / pathology. Magnetic Resonance Imaging. Mediastinum. Reed-Sternberg Cells / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Galactorrhoea-Hyperprolactinaemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11585377.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


16. Rosen CL, DePalma L, Morita A: Primary angiitis of the central nervous system as a first presentation in Hodgkin's disease: a case report and review of the literature. Neurosurgery; 2000 Jun;46(6):1504-8; discussion 1508-10
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary angiitis of the central nervous system as a first presentation in Hodgkin's disease: a case report and review of the literature.
  • It is often diagnosed posthumously, and a high index of suspicion is necessary to make the correct diagnosis on a timely basis.
  • Radiographic examination revealed a right temporal lobe area with edema, and mild contrast enhancement was noted on computed tomography and magnetic resonance imaging.
  • Further workup revealed Hodgkin's disease in the mediastinum.
  • Dexamethasone as well as chemotherapy for Hodgkin's disease was initiated.
  • The patient's symptoms resolved, and she returned to work with her disease in remission.
  • CONCLUSION: Previous reports of central nervous system angiitis have shown an association with Sjogren's syndrome, herpes zoster infection, human immunodeficiency virus, and Hodgkin's disease.
  • A review of the literature revealed a total of 12 patients with central nervous system angiitis and Hodgkin's disease.
  • However, of six patients who presented with central nervous system angiitis and concurrent Hodgkin's disease and who underwent aggressive treatment for both conditions, three had a full recovery, two had a partial recovery, and one died.
  • [MeSH-major] Frontal Lobe / blood supply. Hodgkin Disease / diagnosis. Paraneoplastic Syndromes / diagnosis. Temporal Lobe / blood supply. Vasculitis, Central Nervous System / diagnosis
  • [MeSH-minor] Adult. Biopsy. Cerebral Arteries / pathology. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10834654.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


17. Mudhar HS, Fernando M, Sheard R, Rennie I: Paraneoplastic granulomatous vitritis and retinitis as a presentation of recurrent classical Hodgkin's lymphoma. Int Ophthalmol; 2010 Aug;30(4):341-3
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic granulomatous vitritis and retinitis as a presentation of recurrent classical Hodgkin's lymphoma.
  • We describe a unique case of a patient with an established diagnosis of Hodgkin's lymphoma in clinical remission who later presented with apparent vitreous inflammation.
  • Since the latter can be a paraneoplastic phenomenon of active Hodgkin's lymphoma in distant organ sites, the haematologists were alerted to the possibility of recurrent lymphoma, despite the patient having no clinical symptoms.
  • Repeat body imaging showed enlarged mediastinal lymph nodes, biopsy of which confirmed recurrent Hodgkin's lymphoma.
  • The patient responded well to systemic chemotherapy with resolution of the visual symptoms.
  • This case report illustrates the importance of vitreous biopsy in this clinical setting and how to interpret the significance of granulomas in this context, and outlines a unique vitreo-retinal paraneoplastic granulomatous presentation in the setting of recurrent Hodgkin's lymphoma and how this diagnosis triggered a prompt review of the patient who had no constitutional symptoms, with hopefully a favourable impact on prognosis given the early recurrent disease detection.
  • [MeSH-major] Eye Diseases / etiology. Granuloma / etiology. Hodgkin Disease / complications. Paraneoplastic Syndromes / etiology. Retinitis / etiology. Vitreous Body
  • [MeSH-minor] Aged. Biopsy. Female. Humans. Inflammation / etiology. Inflammation / pathology. Lymph Nodes / pathology. Mediastinum. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2003 May;110(5):1057-60 [12750114.001]
  • [Cites] Eye (Lond). 2008 Oct;22(10):1318-29 [18344965.001]
  • [Cites] Ann Ophthalmol. 1985 Dec;17(12):787-90 [4091380.001]
  • [Cites] N Engl J Med. 1970 Oct 15;283(16):859-61 [5458036.001]
  • (PMID = 20076991.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Turk HM, Ozet A, Ozturk M, Komurcu S, Kuzhan O, Arpaci F, Ozturk B, Safali M: Isolated renal relapse of a case with non-Hodgkin's lymphoma. Med Oncol; 2010 Jun;27(2):434-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated renal relapse of a case with non-Hodgkin's lymphoma.
  • A 29-year-old woman with left pleural effusion and a mass in anterior mediastinum was admitted.
  • Transthoracic needle aspiration from the mass revealed findings consistent with nodular sclerosis variety of Hodgkin's disease.
  • The patient was in remission after six cycles of ABVD followed by mediastinal radiotherapy.
  • Ultrasound guided renal biopsy revealed diffuse large B cell lymphoma.
  • Retrospective re-evaluation of the archival specimens of the mediastinal mass was also consistent with diffuse large B cell lymphoma.
  • After induction chemotherapy (four cycles of DHAP) she underwent high dose chemotherapy (BEAM) and autologous peripheral blood stem cell transplantation.
  • In conclusion, renal involvement during advanced lymphoma is quite common but isolated renal relapse in NHL is a rare situation.
  • Although renal infiltration generally shows a poor prognosis, long-term survival may be achieved with high dose chemotherapy and autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Jan;173(1):239 [15592087.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):134-44 [7832273.001]
  • [Cites] Nephron Clin Pract. 2005;100(3):c86-91 [15824512.001]
  • [Cites] Urology. 1993 Sep;42(3):331-5 [8379037.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1733-8 [14692526.001]
  • [Cites] Hematol Oncol. 1990 Mar-Apr;8(2):105-10 [2344997.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2325-31 [8635103.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3783-5 [17704429.001]
  • [Cites] Turk J Pediatr. 1989 Jan-Mar;31(1):71-7 [2692261.001]
  • [Cites] Eur Urol. 1986;12(5):352-4 [3780803.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):386-91 [3594375.001]
  • [Cites] Saudi J Kidney Dis Transpl. 2006 Sep;17(3):395-8 [16970262.001]
  • [Cites] Int Braz J Urol. 2006 Mar-Apr;32(2):190-2 [16650297.001]
  • [Cites] Clin Adv Hematol Oncol. 2008 Jul;6(7):527-31 [18654120.001]
  • [Cites] Tumour Biol. 2003 Aug-Sep;24(4):172-5 [14654710.001]
  • [Cites] Am J Nephrol. 1994;14(2):148-53 [8080008.001]
  • [Cites] Oncology. 1998 Sep-Oct;55(5):482-6 [9732229.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Apr;21(4):487-92 [4007017.001]
  • [Cites] Gen Diagn Pathol. 1997 Feb;142(3-4):147-53 [9065578.001]
  • [Cites] Eur J Haematol. 2001 Sep;67(3):158-64 [11737248.001]
  • [Cites] Am J Kidney Dis. 1994 Oct;24(4):586-9 [7942815.001]
  • [Cites] J Natl Med Assoc. 2003 Mar;95(3):220-4 [12749682.001]
  • [Cites] J Surg Oncol. 1997 Mar;64(3):207-11 [9121151.001]
  • [Cites] Br J Cancer. 1994 Jul;70(1):154-9 [7517172.001]
  • (PMID = 19437146.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Petrov D, Plochev M, Minchev Ts, Goranov E, Stanoev V: [Anatomical pulmonary resections via median sternotomy]. Khirurgiia (Sofiia); 2006;(4-5):9-11
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During a 10-year period a total of 5 anatomical pulmonary resections (2 lobectomies, 2 pneumonectomies with mediastinal tumor extirpation and 1 polysegmental resection-S1-3) were carried out in 4 patients via median sternotomy.
  • They were operated on for bilateral complicated pulmonary hydatidosis (2), mediastinal teratocarcinoma with right lung invasion and mediastinal Hodgkin's disease after chemotherapy failure.
  • The mean operative time was 161 minutes, and the mean in-hospital stay was 12.75 days.
  • The postoperative period was complicated in 1 patient by pulmonary edema, successfully treated by medication.
  • Teratocarcinoma patient died on the 73th postoperative day with disease progression.
  • [MeSH-minor] Adult. Female. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843915.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


20. Uppin MS, Paul TR, Rajappa S, Gayathri K, Jacob R, Uppin SG: Leukemia as a second malignancy. Indian J Pathol Microbiol; 2007 Jul;50(3):644-7
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study the occurrence of leukemia as a second malignancy following various primary solid and hematological malignancies.
  • The primary malignancies included carcinoma breast (4), multiple myeloma (3) and one each of Hodgkin's lymphoma, mediastinal germ cell tumor, papillary carcinoma thyroid and myxopapillary ependymoma.
  • Ten patients had received chemotherapy with combination radiotherapy in six patients.
  • The commonest type of leukemia was AML-M2.
  • The risk benefit ratio of chemotherapy and radiotherapy should be considered before starting the patients on treatment.
  • A high degree of suspicion and follow up with hematological parameters is required for therapy related complications.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute. Neoplasms, Second Primary. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883171.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Tanaka J, Takamoto S, Ryu T, Ichikawa K, Masuo M, Saito T: [Primary cardiac lymphoma: a case report]. J Cardiol; 2002 Nov;40(5):225-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cardiac lymphoma: a case report].
  • Transvenous biopsy failed to obtain sufficient specimens for the histological diagnosis.
  • The diagnosis was primary cardiac lymphoma on the basis of elevated soluble interleukin-2 receptor and solitary accumulation of gallium-67 in the heart.
  • Chemotherapy was immediately started.
  • After two courses of chemotherapy, the intracardiac tumor disappeared.
  • However, one month later, the tumor relapsed in the anterior mediastinum.
  • Needle biopsy disclosed diffuse B-cell non-Hodgkin's malignant lymphoma.
  • Early diagnosis and immediate chemotherapy are important for the treatment of primary cardiac lymphoma.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12463097.001).
  • [ISSN] 0914-5087
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Receptors, Interleukin-2
  •  go-up   go-down


22. Vander Els NJ, Sorhage F, Bach AM, Straus DJ, White DA: Abnormal flow volume loops in patients with intrathoracic Hodgkin's disease. Chest; 2000 May;117(5):1256-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal flow volume loops in patients with intrathoracic Hodgkin's disease.
  • STUDY OBJECTIVES: To study the incidence of upper airway obstruction, as measured on the flow volume loop (FVL), in patients with bulky mediastinal Hodgkin's disease; to correlate the FVL with CT of the chest; and to follow the changes in the FVL after treatment of the tumor.
  • DESIGN: Retrospective study of pulmonary function tests (PFTs) and chest CTs performed as part of a clinical trial for Hodgkin's disease.
  • PATIENTS: Twenty-five patients (15 men and 10 women; age range, 20 to 57 years) with bulky mediastinal Hodgkin's disease enrolled in a clinical trial of chemotherapy followed by external beam radiation therapy.
  • MEASUREMENTS AND RESULTS: Fourteen of 25 patients (56%) had an abnormal FVL prior to therapy; after chemotherapy, only 7 of 25 patients (28%) had an abnormal FVL.
  • CONCLUSION: FVL abnormalities suggesting upper airway obstruction occurred in > 50% of patients with bulky mediastinal Hodgkin's disease.
  • [MeSH-major] Airway Obstruction / diagnosis. Hodgkin Disease / diagnosis. Lung Volume Measurements. Mediastinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Airway Resistance / physiology. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10807808.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


23. Alobeidy ST, Ilowite J, Donovan V, Selbs E, Badler R, Katz DS: Calcification in untreated mediastinal Hodgkin's lymphoma. J Thorac Imaging; 2001 Oct;16(4):304-6
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcification in untreated mediastinal Hodgkin's lymphoma.
  • Calcification is very rarely reported in untreated thoracic lymphoma.
  • However, calcification can occur (although uncommonly) in lymphoma following chemotherapy or radiation, and in areas of scaring or fibrous healing.
  • The authors describe the case of a pregnant woman with a large mediastinal mass that contained calcifications visible on both chest radiography and thoracic computed tomography, which proved to be Hodgkin's lymphoma.
  • [MeSH-major] Hodgkin Disease / pathology. Mediastinal Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Calcinosis / pathology. Diagnosis, Differential. Female. Humans. Pregnancy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11685097.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Nikpoor N, Aliabadi P, Diaz L, Mannting F: Long-term follow-up of residual mediastinal-hilar Ga-67 uptake after treatment for Hodgkin's and non-Hodgkin's lymphomas: what degree of Ga-67 uptake is significant? Clin Nucl Med; 2000 Dec;25(12):959-62
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of residual mediastinal-hilar Ga-67 uptake after treatment for Hodgkin's and non-Hodgkin's lymphomas: what degree of Ga-67 uptake is significant?
  • PURPOSE: Ga-67 planar and SPECT images of 85 patients after treatment for mediastinal-hilar (M-H) lymphoma were reviewed retrospectively.
  • Forty-seven patients had Hodgkin's disease and 38 patients had non-Hodgkin's lymphoma.
  • The entire period was 7 years after diagnosis.
  • The main goal was visual assessment of the significance of mild (grades 1 or 2) Ga-67 uptake in the M-H area as compared with Ga-67 uptake in bone marrow.
  • METHODS: Residual Ga-67 mediastinal uptake after a complete course of chemotherapy or other treatments was defined as normal (no residual) M-H uptake, borderline (M-H residual uptake with intensity less than that or equal to the sternum, spine, or both), and abnormal (M-H residual uptake with intensity greater than that of the sternum or spine).
  • RESULTS: Among the 38 patients (45%) with no residual M-H uptake, four (one Hodgkin's disease and three non-Hodgkin's lymphoma) experienced recurrence: two in the mediastinum and two in the abdomen.
  • Among the 45 patients (53%) with borderline M-H uptake, five experienced recurrence: two in the mediastinum and three in other sites.
  • The two patients (2%) with abnormal (M-H) uptake never responded to treatment.
  • [MeSH-major] Gallium Radioisotopes. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Mediastinal Neoplasms / radionuclide imaging. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radionuclide imaging. Prognosis. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11129161.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes
  •  go-up   go-down


25. Castellini C, De Nitto F, Bonomo S, Bottura D, Mazzola F, Ballarin A, Rosa G: [Fournier's gangrene in a patient with Hodgkin's disease: a clinical case]. Chir Ital; 2001 Nov-Dec;53(6):905-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fournier's gangrene in a patient with Hodgkin's disease: a clinical case].
  • The authors report a case of Fournier's gangrene in a 54-year-old patient subjected 6 days earlier to chemotherapy for mediastinal Hodgkin's disease.
  • The Patient underwent emergency surgery with multiple, communicating incisions in the inguinal, perineal and scrotal areas, with the removal of necrotic tissue and daily washing with physiological solution and 12% H2O2.
  • He also received antibiotic treatment with metronidazole and gentamicin and 5 cycles of high-pressure oxygen therapy, with disappearance of pain and fever and good local tissue repair.
  • [MeSH-major] Fournier Gangrene / etiology. Hodgkin Disease / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11824071.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


26. Krugmann J, Sailer-Höck M, Müller T, Gruber J, Allerberger F, Offner FA: Epstein-Barr virus-associated Hodgkin's lymphoma and legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A. Hum Pathol; 2000 Feb;31(2):253-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated Hodgkin's lymphoma and legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A.
  • We describe the case of a 53-month-old girl with juvenile rheumatoid arthritis (JRA), complicated by the occurrence of Hodgkin's lymphoma and Legionella pneumophila infection during immunosuppressive treatment with methotrexate (MTX) and cyclosporine A (CSA).
  • The girl had received variable anti-inflammatory combination therapy, including MTX for 28 months and CSA for 3 months.
  • Thirty-six months after the onset of arthritis, the girl presented with an enlargement of the lymph nodes of the mediastinum, the hilum of the lungs, and the abdomen.
  • Concomitantly, a diagnosis of Legionella pneumonia was rendered.
  • Autopsy showed Epstein-Barr virus (EBV)-associated nodular sclerosing Hodgkin's lymphoma.
  • The present case is the second reported to occur in a child, and it lends support to the hypothesis that immunosuppressive treatment may contribute to an increased risk of the development of EBV-associated lymphoproliferative disorders (LPD) in pediatric patients suffering from JRA.
  • [MeSH-major] Arthritis, Rheumatoid / drug therapy. Epstein-Barr Virus Infections / etiology. Hodgkin Disease / virology. Immunosuppressive Agents / adverse effects. Legionnaires' Disease / etiology


27. Wróbel G, Kazanowska B, Chybicka A, Jeleń M, Małdyk J, Sowińska E, Balcerska A, Balwierz W, Bubała H, Kołakowska-Mrozowska B, Kołtan A, Korzon M, Kowalczyk J, Krawczuk-Rybak M, Maciejka-Kapuścińska L, Matysiak M, Płoszyńska A, Popadiuk S, Solarz E, Sońta-Jakimczyk D, Sopyło B, Stańczak E, Stefaniak J, Stefańska K, Wachowiak J, Wieczorek M, Wysocki M: [Progress in the treatment of non-Hodgkin's lymphoma (NHL) in children. The report of Polish Pediatric Leukaemia/lymphoma Study Group (PPLLSG)]. Przegl Lek; 2004;61 Suppl 2:45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progress in the treatment of non-Hodgkin's lymphoma (NHL) in children. The report of Polish Pediatric Leukaemia/lymphoma Study Group (PPLLSG)].
  • Treatment results of non-Hodgkin lymphoma (NHL) in children has been shown in this study.
  • From 1979 to 2003 children were registered with the diagnosis of NHL in oncology centers of Polish Pediatric Leukaemia/Lymphoma Study Group, a group of 397 patients with NHL B, 222 pts with NHL T and 54 pts with anaplastic large cell lymphoma (ALCL).
  • The predominant primary site of disease was mediastinum (59.3%).
  • The majority were Burkitts type and presented abdominal location (50%).
  • 80% with disseminated disease.
  • The median time of follow up was 53 months.
  • Peripheral nodes were the most often primary location (40%), than mediastinum (24%) and abdomen (21%).
  • Despite great progress in the therapy of NHL in children during 20 years of observation, the results are not satisfactory in disseminated stages.
  • Major surgery in advanced stages is not recommended since it delays chemotherapy and fails to improve overall survival.
  • Early detection of neoplasm is one of the most important efforts to improve therapy success.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / epidemiology. Adolescent. Child. Child, Preschool. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / epidemiology. Poland / epidemiology. Prognosis. Retrospective Studies. Risk Factors. Secondary Prevention. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686045.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


28. Nasta SD, Carrum GM, Shahab I, Hanania NA, Udden MM: Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma; 2002 Feb;43(2):423-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy.
  • We describe an HIV-infected 44-year-old man who presented 1 month after discontinuation of HAART therapy with a large mass extending from the mediastinum, enclosing the heart and extending through the diaphragm to the epigastric region.
  • Biopsies subsequently revealed a highly aggressive non-Hodgkin's lymphoma (NHL) producing sheets of cells with an organoid distribution.
  • These studies were supportive of a diagnosis of a plasmablastic lymphoma.
  • He was found on follow-up a month later to have complete resolution of his bulky mediastinal mass.
  • He remained free of disease for 3 months with subsequent rectal and abdominal recurrence.
  • Treatment with CHOP chemotherapy with filgrastim support was begun which resulted in another remission.
  • Plasmablastic lymphoma is now reported in some studies to account for 2.6% of all HIV-related NHL.
  • Therapy with standard regimens has variable response.
  • One case has been reported with a 3.5 year disease free survival.
  • The regression of disease after resumption of HAART therapy alone in this patient suggests that HAART has an important role in the treatment of lymphoma in the HIV infected patient.
  • [MeSH-major] Anti-HIV Agents / administration & dosage. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. HIV Infections / complications. HIV Infections / drug therapy. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / virology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / virology. Male. Remission Induction

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11999580.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


29. Petersdorf SH, Wood DE: Lymphoproliferative disorders presenting as mediastinal neoplasms. Semin Thorac Cardiovasc Surg; 2000 Oct;12(4):290-300
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoproliferative disorders presenting as mediastinal neoplasms.
  • The mediastinum is an uncommon location for presentation of these heterogeneous disorders, but involvement of the mediastinum may be the sole site of disease for several aggressive lymphomas.
  • Both Hodgkin's disease and non-Hodgkin's lymphoma may present in the mediastinum.
  • The most common types of non-Hodgkin's lymphoma involving the mediastinum include lymphoblastic lymphoma and mediastinal large cell lymphoma.
  • These lymphomas most commonly develop in the anterior mediastinum but may be seen in the middle and posterior mediastinum.
  • Symptoms associated with a mediastinal presentation of a lymphoproliferative disorder are often attributable to compression of mediastinal structures (eg, superior vena cava syndrome) or invasion of thoracic structures such as the pericardium or pleura.
  • Although staging can be performed with routine imaging studies, surgical intervention is often required to ensure accurate histologic diagnosis of these lymphomas.
  • Once a diagnosis has been established, therapeutic modalities usually include chemotherapy and/or radiotherapy.
  • [MeSH-major] Lymphoma. Mediastinal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 by W.B. Saunders Company
  • (PMID = 11154724.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 41
  •  go-up   go-down


30. Ripp JA, Loiue DC, Chan W, Nawaz H, Portlock CS: T-cell rich B-cell lymphoma: clinical distinctiveness and response to treatment in 45 patients. Leuk Lymphoma; 2002 Aug;43(8):1573-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell rich B-cell lymphoma: clinical distinctiveness and response to treatment in 45 patients.
  • T-cell rich B-cell lymphoma (TCR-BCL) is a recently described pathologic diagnosis without a place among traditional lymphoma classification systems.
  • In the past, TCR-BCL has been included among other diagnoses, in particular lymphocyte predominant Hodgkin's disease (LPHD).
  • The study of TCR-BCL cohorts may elucidate clinical distinctiveness, response to therapy, and the effect of treatment regimen on outcome.
  • Our patients presented most commonly as males in their fourth decade with advanced stage disease.
  • Conventional combination chemotherapy regimens were utilized for an aggressive non-Hodgkin's lymphoma (NHL) diagnosis in 26 and for a Hodgkin's disease (HD) diagnosis in 10.
  • Disease-free survival (DFS) was significantly better for NHL (36%) vs. HD (10%) directed chemotherapy at 3 years (p = 0.003).
  • Overall survival at 3 years was not statistically different (62 vs. 79%) due to successful salvage therapy in both groups.
  • Advanced stage, extranodal disease, involvement of the mediastinum, mesentery and/or spleen are clinical clues to a TCR-BCL diagnosis.
  • Chemotherapy directed to a NHL diagnosis rather than HD results in a significant improvement in disease-free survival.
  • Initial Hodgkin's disease-directed (HD-directed) chemotherapy should be avoided, although salvage transplantation may result in prolonged survival.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Lymphoma, Non-Hodgkin / therapy. Lymphoma, T-Cell / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12400599.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


31. Schneider T, Tóth E, Molnár Z, Várady E, Deák B, Horváth A, Horváth GI, Eid H, Schneider K, Lovey J, Keresztes S, Esik O, Lengyel Z, Rosta A: [Treatment of primary mediastinal large B-cell lymphomas]. Orv Hetil; 2004 Dec 12;145(50):2531-7
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of primary mediastinal large B-cell lymphomas].
  • INTRODUCTION: Primary mediastinal large B-cell non-Hodgkin's lymphoma is a relatively rare disease with specific clinical symptoms.
  • This tumour originates from a subset of B-cells of the thymus and at the time of the diagnosis the disease is predominantly localised in the mediastinum.
  • This is the only lymphoma subtype which can only be defined by the combination of clinical and pathologic features.
  • Analysis with DNA microarrays verified that primary mediastinal and diffuse large B-cell lymphomas are different diseases.
  • AIMS: Comparing the effectiveness of two types of anthracycline-based standard chemotherapy regimens and the evaluation of the prognostic markers which are applied in large B-cell lymphomas.
  • METHODS: 27 patients with primary mediastinal lymphoma were treated by the authors with anthracycline-based polychemotherapy with complementary radiotherapy from January 1995 to December 2002.
  • 9 additional patients (33%) achieved partial remission, while in 3 cases (11%) the treatment was ineffective.
  • The patients who failed to achieve complete remission were subsequently treated with more intensive chemotherapy.
  • Afterwards, those patients who were chemosensitive, underwent high-dose chemotherapy with autologous peripheral blood stem-cell transplantation.
  • The chemoresistant patients received palliative chemotherapy.
  • CONCLUSION: The authors found that the procarbazine, prednisolone, adriamycin, cyclophosphamide, etoposide, cytosine-arabinoside, bleomycin, vincristine, methotrexate treatment was more effective than the cyclophosphamide, adriamycin, vincristine, prednisolone combination.
  • The results with the new standard of combined immuno-chemotherapy (rituximab--cyclophosphamide, adriamycin, vincristine, prednisolone) seem to be hopeful and more effective than earlier treatments.
  • [MeSH-major] Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Mediastinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prednisolone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662753.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


32. Belal AA, Allam A, Kandil A, El Husseiny G, Khafaga Y, Al Rajhi N, Ahmed G, Gray A, Ajarim D, Schultz H, Ezzat A: Primary thyroid lymphoma: a retrospective analysis of prognostic factors and treatment outcome for localized intermediate and high grade lymphoma. Am J Clin Oncol; 2001 Jun;24(3):299-305
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary thyroid lymphoma: a retrospective analysis of prognostic factors and treatment outcome for localized intermediate and high grade lymphoma.
  • Non-Hodgkin's lymphoma presenting in the thyroid gland is uncommon.
  • A review of the King Faisal Specialist Hospital and Research Centre (KFSH & RC) experience was performed to assess treatment outcome and prognostic factors in this rare extranodal presentation of localized lymphoma.
  • Eight patients who had stage III or IV disease, low grade, or did not complete their prescribed treatment were excluded from the study.
  • There were 38 female and 14 male patients with a median age of 59.5 years at the time of diagnosis (range: 10-87 years).
  • All 52 patients had non-Hodgkin's lymphoma of intermediate (94%) or high (6%) grade.
  • Detailed staging was carried out in all patients; 16 patients (31%) had disease confined to the thyroid gland (stage IE), whereas 36 (69%) had associated disease in cervical lymph nodes and/or the mediastinum (stage IIE) disease.
  • A total of 18 patients (35%) were treated with a single-modality treatment--radiotherapy alone in 2, chemotherapy alone in 13, and surgery alone in the remaining 3 patients.
  • There were no significant differences in outcome between those treated with single-modality and those with combined-modality therapy.
  • A univariate analysis showed that the presence of mediastinal lymph node involvement was the most important prognostic factor affecting both RFS and OS.
  • Age, sex, stage, histology, lactic acid dehydrogenase level, tumor bulk, and the treatment modality were not found to correlate with RFS or OS.
  • Mediastinal involvement and PS were found to be the most important independent prognostic factors influencing RFS and OS.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11404505.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Chajari M, Lacroix J, Peny AM, Chesnay E, Batalla A, Henry-Amar M, Delcambre C, Génot JY, Fruchard C, Bardet S: Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography? Eur J Nucl Med Mol Imaging; 2002 Mar;29(3):380-7
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?
  • The usefulness and complementarity of gallium (67Ga) scintigraphy and computed tomography (CT) in the management of patients with lymphoma have been extensively demonstrated.
  • As fusion imaging techniques between single-photon emission tomography (SPET) and CT have been developed recently, we investigated whether use of CT/67Ga SPET fusion imaging could help in the interpretation of 67Ga scintigraphy.
  • From November 1999 to May 2001, 52 consecutive fusion studies were performed in 38 patients [22 patients with Hodgkin's disease (HD) and 16 patients with non-Hodgkin's lymphoma (NHL)] as part of pre-treatment staging (n=13), treatment evaluation (n=20) or evaluation of suspected recurrence (n=19).
  • Image fusion was considered to be of benefit in 12/52 (23%) studies which were performed for initial staging (n=4), treatment evaluation (n=4) or evaluation of suspected recurrence (n=4).
  • In these cases, image fusion allowed either confirmation and/or localisation of pathological gallium uptake (n=10) or detection of lesions not visible on CT scan (n=2).
  • At the thoracic level, fusion also proved useful for demonstrating clearly the relationships of abnormal foci to the pleura, hepatic dome, mediastinum, ribs or thoracic spine.
  • Clinical management was altered by fusion imaging in one patient (chemotherapy was given instead of radiotherapy) and was potentially affected in three other patients (in that, in conjunction with other factors, the results of fusion imaging had an influence on the decision regarding use of irradiation and especially the treatment volume).
  • In conclusion, CT/67Ga SPET fusion imaging allowed precise localisation of gallium uptake and correct attribution to the involved viscera, thereby altering the diagnosis in 20%-25% of studies in comparison with CT and 67Ga SPET analyses alone.
  • CT/67Ga SPET fusion therefore appears valuable in facilitating the interpretation of 67Ga scintigraphy and we recommend its use in patients with lymphoma when CT and 67Ga scintigraphy are planned.
  • [MeSH-major] Citrates. Gallium. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002715.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Citrates; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


34. Veronesi G, Spaggiari L, Solli PG, Leo F, Villa G, Pastorino U: Postpneumonectomy-like syndrome after chemoradiation therapy for lymphoma. Ann Oncol; 2002 Dec;13(12):1945-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postpneumonectomy-like syndrome after chemoradiation therapy for lymphoma.
  • Postpneumonectomy syndrome (PPS) is a rare complication of pneumonectomy due to an excessive mediastinal shift producing compression of the main bronchus or a lobe bronchus on the aorta or the spine.
  • We report an exceptional case in which an extreme mediastinal shift was due to fibrosis and complete atelectasis of the left lung, as a complication of chemoradiation treatment for recurrent mediastinal Hodgkin's lymphoma.
  • This condition, associated with a further recurrence of the disease, indicated a postpneumonectomy-like syndrome.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12453864.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone
  •  go-up   go-down






Advertisement